Company profile for Suzhou Forlong Biotechnology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Forlong Biotechnology is a clinical-stage biotech company developing next-generation cytokine therapeutics through advanced synthetic immunology. With four core technology platforms, we aim to overcome the challenges in cytokine drug development and transform cancer treatment. Focused on tumor immunology, our engineered cytokine combinations target key stages of the cancer-immunity cycle. Our lead asset, FL115—an IL-15 super...
Forlong Biotechnology is a clinical-stage biotech company developing next-generation cytokine therapeutics through advanced synthetic immunology. With four core technology platforms, we aim to overcome the challenges in cytokine drug development and transform cancer treatment. Focused on tumor immunology, our engineered cytokine combinations target key stages of the cancer-immunity cycle. Our lead asset, FL115—an IL-15 super agonist—has shown strong safety and efficacy in clinical trials, achieving partial response as a monotherapy.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
310, Building 1, No. 19 Yong 'an Road, Suzhou
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

BioProcess International US West

Not Confirmed

envelop Contact Supplier

BioProcess International US West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-01-07/forlong-biotechology-announced-activation-of-phase-ibii-study-of-fl115-il-15-superagonist-in-comb

PHARMIWEB
07 Jan 2026

https://www.businesswire.com/news/home/20251030436980/en/Forlong-Biotechology-to-Present-Clinical-Data-from-FL115-a-novel-interleukin-15-IL-15-superagonist-in-Late-breaking-Session-at-40th-SITC-Annual-Meeting

BUSINESSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20251030585675/en/Forlong-Dosed-First-Patient-in-Phase-2-Clinical-Trial-of-FL115-a-novel-interleukin-15-IL-15-superagonist-for-nonmuscle-invasive-bladder-cancer-NMIBC

BUSINESSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20251022986359/en/Forlong-Biotechology-Announces-Collaboration-Agreement-with-Henlius-to-Develop-Innovative-Cancer-Immunotherapy-with-an-Engineered-Cytokine

BUSINESSWIRE
22 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-14/forlong-biotechnology-receives-milestone-payment-as-partner-submits-ind-for-a-protein-therapy-using

PHARMIWEB
14 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty